Vaxart

Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) oral vaccine platform. Its investigational vaccines are administered using a room temperature-stable tablet, rather than by injection. It is developing prophylactic vaccine candidates that target a range of infectious diseases, including SARS-CoV-2, norovirus, seasonal influenza and respiratory syncytial virus (RSV). The company was founded in 2004 and is headquartered in South San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Vaxart reports solid Q1 earnings, progresses in vaccine development

Vaxart's Q1 2024 performance reflects financial stability and progress in vaccine development, particularly with positive Phase I trial results for their norovirus vaccine.
While the company faces challenges in funding, manufacturing, and program prioritization, opportunities lie in advancing COVID-19 vaccine trials and regulatory engagements.
By addressing concerns and leveraging opportunities effectively, Vaxart can strengthen its position in the vaccine market and drive future growth and innovation.

Vaxart reports strong Q3 revenue, advances in COVID and norovirus

Vaxart's Q3 2024 earnings call highlighted revenue from government contracts, progress in COVID, norovirus, and HPV programs, and promising trial data.
The company faces challenges in study enrollment, resource allocation, and regulatory compliance but remains open to collaborations and global vaccine development.
With a cash runway into 2026, Vaxart is well-positioned to leverage market demand for their oral pill vaccine candidates and drive future growth.
Strong performance, constructive FDA feedback, and market opportunities position Vaxart for continued success in vaccine development and partnerships.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology oral vaccine platform. Its investigational vaccines are administered using a room temperature-stable tablet, rather than by injection. It is developing prophylactic vaccine candidates that target a range of infectious diseases, including SARS-CoV-2, norovirus, seasonal influenza and respiratory syncytial virus (RSV). The company was founded in March 2004 and is headquartered in South San Francisco, CA.

Eli Lilly

Moderna

Regeneron Pharmaceuticals

Sanofi

The whole world has pinned hopes on pharmaceutical and biotech companies to create drugs and vaccine to help combat COVID-19.

Buy 5 Top Medical Stocks on Coronavirus  Drug Trial Results

GlaxoSmithKline

Inovio Pharmaceuticals

Johnson & Johnson

Just like the flu vaccine, pharmacists should be empowered to administer the COVID-19 vaccine to patients in every state.

Expand Pharmacists’ Authority To Promote COVID-19 Vaccine Access

ProShares Long Online/Short Stores ETF

Co-Diagnostics

CrowdStrike

Domino's Pizza

Emergent BioSolutions

JD.com

Zoom Video

Inside the top-performing sectors of Q1 and their winning stocks.

Top Sectors of Q1 & Their Winning Stocks

Novavax

Roku

Unlike the broader market, these stocks to buy have managed to hold up strong amid the ongoing public health crisis.

5 Stocks to Buy That Are Holding Strong While Everything Else Crumbles

AbbVie

Fast-track approval for coronavirus drug trials is encouraging drug developers. Here are four stocks that can make the most of this phase.

Coronavirus Drug Development Race to Boost These 4 Stocks

Amazon

Clorox

Costco

Even though several companies have suffered badly from the COVID-19 outbreak, here're five that stand to benefit from the pandemic.

Here're the 5 Big Winners from the Coronavirus Pandemic

Emergent BioSolutions (EBS) teams up with Vaxart to support development of the latter's oral vaccine candidate for treating coronavirus disease.

Emergent (EBS) to Help Vaxart Develop Coronavirus Vaccine

Vaxart Inc (NASDAQ: VXRT) shares were advancing Wednesday following an update from the company on its COVID-19 vaccine program.

Vaxart, Emergent Biosolutions Partner On Coronavirus Vaccine Development

Shares of Vaxart Inc. VXRT, +63.56% jumped 48% in premarket trading on Wednesday after the company said it had signed a deal with Emergent BioSolutions Inc.

Vaxart: Emergent to manufacture Vaxart's experimental COVID-19 vaccine

Oral Vaccines based on Proprietary VAAST™ Platform Offer Potential Key Advantages in Global Quest to Develop Coronavirus Vaccine Oral Vaccines based on Proprietary VAAST™ Platform Offer Potential Key Advantages in Global Quest to Develop Coronavirus Vaccine

VAXART ANNOUNCES IT ENTERED INTO AN AGREEMENT WITH EMERGENT BIOSOLUTIONS FOR THE DEVELOPMENT AND MANUFACTURING OF ORAL CORONAVIRUS (COVID-19) VACCINE CANDIDATE

GAITHERSBURG, Md., March  18, 2020  (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has entered into an agreement with Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biotechnology company, whereby Emergent has agreed to utilize its molecule-to-market contract development and manufacturing (CDMO) services to develop and manufacture Vaxart’s experimental oral vaccine candidate for coronavirus disease (COVID-19). Development services will begin immediately, and upon Vaxart’s election, Emergent agrees to produce clinical material expected to enable Vaxart to initiate a Phase 1 clinical study anticipated early in the second half of 2020. Vaxart’s oral recombinant vaccine candidate is based on its proprietary VAAST™ platform.

EMERGENT BIOSOLUTIONS SIGNS DEVELOPMENT AND MANUFACTURING AGREEMENT WITH VAXART FOR THEIR EXPERIMENTAL ORAL VACCINE CANDIDATE FOR CORONAVIRUS DISEASE

Altimmune

Applied DNA Sciences

BioNTech SE

The outbreak of COVID-19 caused by the new coronavirus SARS-CoV-2 is roiling the global economy.

8 Biotechs With Coronavirus Vaccines In Development

Cocrystal Pharma

Gilead Sciences

NanoViricides

Pfizer

The COVID-19 virus has sent the market and the global economy into a tailspin. The Organisation for Economic Co-operation and Development slashed its global growth forecast for 2020 Monday by 0.5 points to 2.5% versus already-weak 2.9% growth in 2019.

How Close Are Biotechs To Bringing A COVID-19 Treatment To Market?

Aduro BioTech

Rite Aid

Sharps Compliance

TeleNav

After a painful stretch, small-cap U.S. stocks should rebound on a few tailwinds.

5 Reasons to Buy These Small-Cap Stocks Now

Global markets lost $6 trillion in the week ended Feb 29 as coronavirus triggered sharp selloff. Here's how to play the dip.

3 Correction-Defying Bets to Buy as Markets Brave Coronavirus

President Donald Trump asks pharmaceutical companies working on making vaccines or treatments for coronavirus to accelerate development.

Trump Asks Pharma Firms to Step Up Coronavirus Vaccine Work

Here we discuss 5 biotech stocks that outperformed the industry amid the U.S. market slump.

5 Biotechs That Escaped the Coronavirus Onslaught Last Week

Stamps.com

Uniti Group

Wall Street has entered into the correction territory after steep coronavirus-induced selloffs in February. But these stocks have gained massively.

Market in Correction: 5 Stocks Resist Virus Attack in February

SOUTH SAN FRANCISCO, Calif., Feb.  27, 2020  (GLOBE NEWSWIRE) -- Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that it has entered into definitive agreements with several institutional investors for the issuance and sale of 4,000,000 shares of its common stock and warrants to purchase up to 2,000,000 shares of its common stock, at a combined purchase price of $2.50 per share and associated warrant, for aggregate gross proceeds of $10.0 million, in a registered direct offering priced at-the-market under Nasdaq rules.

Vaxart Announces $10.0 Million Registered Direct Offering Priced At-the-Market

Healthcare companies are trying to find a cure and contain the coronavirus outbreak. This keeps the industry in focus

4 Healthcare Stocks to Gain as Coronavirus Threat Looms Large

As of late, it has definitely been a great time to be an investor in Vaxart, Inc. (VXRT).

Vaxart, Inc. (VXRT) Shares March Higher, Can It Continue?

Vaxart (VXRT) begins a program to develop a vaccine candidate to counter the new coronavirus infection. Shares jump.

Vaxart (VXRT) to Make Vaccines to Check Coronavirus, Stock Up

Shares of Vaxart Inc. rocketed 54% on heavy volume in afternoon trading, putting them on track for the first close above the $1 mark in nearly 10 months, after the biotechnology company said it "initiated" a program to develop a coronavirus vaccine.

Vaxart's stock rockets on heavy volume after initiating coronavirus vaccine development program

Vaxart Announces Initiation of Coronavirus Vaccine Program

Pulmatrix

Trillium Therapeutics

January has turned out great for biotech stocks thanks to the coronavirus outbreak as well as a general upbeat trend.

The Wining Sector & Its Top Stocks in Virus-Infected January

News for Vaxart Stock (VXRT)